Ethiopia: Loan from United Nations Fund Allows Food and Agriculture Organization (FAO) to Scale Up Fertilizers for Farmers in TigrayRead more How Choosing the Right Printer Helps Small Businesses and Content Creators to Save Time, Maximise Productivity and Achieve GrowthRead more The United States Contributes USD $223 Million to Help World Food Programme (WFP) Save Lives and Stave Off Severe Hunger in South SudanRead more Eritrea: World Breastfeeding WeekRead more Eritrean community festival in Scandinavian countriesRead more IOM: Uptick in Migrants Heading Home as World Rebounds from COVID-19Read more Network International & Infobip to offer WhatsApp for Business Banking Services to Financial Institution Clients across AfricaRead more Ambassador Jacobson Visits Gondar in the Amhara Region to Show Continued U.S. Support for the Humanitarian and Development Needs of EthiopiansRead more Voluntary Repatriation of Refugees from Angola to DR Congo ResumesRead more Senegal and Mauritania Are Rich in Resources, Poor in Infrastructure, Now Is the Time to Change That Read more

BioNTech: COVID-19 vaccine tests show positive results

Print Friendly and PDF

Jul 14, 2020 - 01:24 AM

ANKARA (AA) – German-based biotech firm BioNTech announced that it had observed positive results in ongoing research with US drug giant Pfizer to develop a vaccine against the novel coronavirus.

Preliminary results were released by the companies and are under scientific peer-review for publication.

According to the early data, the vaccine generated antibodies against the virus stronger than the average recovered COVID-19 patient.

“These preliminary data are encouraging, showing that BNT162b1 [vaccine candidate] which exploits RBD SARS-CoV-2 as a target antigen is able to produce neutralizing antibody responses in humans at or above the levels observed in convalescent sera — and that it does so at relatively low dose levels. We look forward to providing further data updates on BNT162b1,” said Ugur Sahin, CEO and co-founder of BioNTech, in the statement.

In a clinical trial performed with pharmaceutical company Pfizer in the US, 24 people aged between 18 and 55 who received two doses of the vaccine had “significantly elevated” antibodies that fight the disease within four weeks of their first injection.

The study had 45 participants in total, some receiving placebos and some receiving higher doses of the vaccine.

“These preliminary data, together with additional preclinical and clinical data being generated, will be used by the two companies to determine a dose level and select among multiple vaccine candidates to seek to progress to a large, global Phase 2b/3 safety and efficacy trial,” said the statement.

“That trial may involve up to 30,000 healthy participants and is anticipated to begin in late July 2020, if regulatory approval to proceed is received. The preliminary clinical data from this ongoing study has been submitted for potential publication in a peer-reviewed journal and is available on an online preprint manuscript server,” it added.

Since originating in China last December, the pandemic has claimed more than 512,000 lives in 188 countries and regions.

Over 10.5 million cases have been reported worldwide, while recoveries have exceeded 5.38 million so far, according to figures compiled by the US’ Johns Hopkins University. (Busra Nur Bilgic Cakmak)

ZONNTECH.COM uses both Facebook and Disqus comment systems to make it easier for you to contribute. We encourage all readers to share their views on our articles and blog posts. All comments should be relevant to the topic. By posting, you agree to our Privacy Policy. We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, name-calling, foul language or other inappropriate behavior. Please keep your comments relevant and respectful. By leaving the ‘Post to Facebook’ box selected – when using Facebook comment system – your comment will be published to your Facebook profile in addition to the space below. If you encounter a comment that is abusive, click the “X” in the upper right corner of the Facebook comment box to report spam or abuse. You can also email us.